RNS Number : 5971Q
Pharma C Investments PLC
22 February 2023

22 February 2023

Pharma C Investments PLC

("Pharma C" or the "Company")

Appointment of Director

Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry with a particular focus on companies that provide ancillary products and services to the medicinal cannabis sectors, is pleased to announce the appointment of Mr. Jeremy Woodgate to the Board of Directors, with immediate effect.

Gavin Sathianathan, Investment Strategy Director, commented:

"I am pleased to welcome Jeremy to the board of Pharma C and look forward to working closely with him to deliver on our mission to invest in high-growth companies."

Jeremy Woodgate

Mr. Woodgate graduated as an Engineer in 2008 and started his career as a corporate stockbroker specializing in raising finance for resources companies with gold companies a particular focus. Working at Pareto Securities (formerly Ocean Equities), Mr. Woodgate was promoted to Head of Trading in 2010 and became a Partner in 2012, working on large equity and bond transactions primarily in the resources and shipping sectors. In 2015, Mr. Woodgate founded Smaller Company Capital Ltd. which listed the first publicly traded Blockchain business. Smaller Company Capital Ltd. went on to finance and list numerous technology and resources companies. Mr. Woodgate now sits on the board of a number of companies across the resource, tech and sports sectors.

Mr. Woodgate has an interest of 2,528,617 Common Shares in the Company.

Current Directorships	**Former Directorships and/or partnerships (within the last five years)**
Shelby Logistics Limited	Vue Carbon Limited
White Bear Resources Ltd	Kryptonite Can Limited
Axies Ventures Ltd	Kryptonite 1 Limited
Ludus Gaming Ltd	Providence Capital Partners Limited
One Hundred Group Ltd	
States Bridge Capital Limited	
JJW Holdings Limited	
Smaller Company Capital Limited	

Except as set out above, there is no further information regarding Jeremy Woodgate that is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

- ENDS -

The Director of the Company accepts responsibility for the contents of this announcement.

This announcement contains inside information for the purposes of Article 7 of the EU Regulation 596/2014 as it forms part of the UK law by virtue the European Union (Withdrawal) Act 2018

For further information please visit www.pharmacinvestments.com

For additional information please contact:

Pharma C Investments

Gavin Sathianathan, Investment Strategy Director

gavin@pharmacinvestments.com

Novum Securities (AQSE Corporate Adviser)

Tel: +44 207 399 9400

David Coffman

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFFLFLXLLEBBX